Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Cash Flow (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Cash Flow for 16 consecutive years, with -$444000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 91.26% to -$444000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $236000.0, a 101.51% increase, with the full-year FY2025 number at $236000.0, up 101.51% from a year prior.
  • Net Cash Flow was -$444000.0 for Q4 2025 at Anika Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.6 million in Q3 2023 to a low of -$14.7 million in Q2 2023.
  • A 5-year average of -$1.9 million and a median of -$1.3 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 1433.3% in 2023, then surged 747.91% in 2025.
  • Anika Therapeutics' Net Cash Flow stood at $3.3 million in 2021, then tumbled by 141.95% to -$1.4 million in 2022, then surged by 254.96% to $2.1 million in 2023, then crashed by 337.34% to -$5.1 million in 2024, then surged by 91.26% to -$444000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Net Cash Flow are -$444000.0 (Q4 2025), $5.1 million (Q3 2025), and -$549000.0 (Q2 2025).